12 results
Vasculitis Management - ACR/VF 2021 Guidelines for Treatment & Management
 • Giant Cell Arteritis (GCA)
 •
Vasculitis Management - ACR ... Guidelines for Treatment ... Polyangiitis (GPA ... #ACR2021 #Guidelines ... #algorithm #rheumatology
Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021
Polyangiitis (GPA ... Management Algorithm - ACR ... #Management #Treatment ... #ACR2021 #Guidelines ... #algorithm #rheumatology
Eosinophilic Granulomatosis with Polyangiitis (EGPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Active
) - ANCA Vasculitis ... Management Algorithm - ACR ... Vasculitis #Management #Treatment ... #ACR2021 #Guidelines ... #algorithm #rheumatology
Giant Cell Arteritis (GCA) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Visual Symptoms/Loss or
Cell Arteritis (GCA ... Management Algorithm - ACR ... Vasculitis #Management #Treatment ... #ACR2021 #Guidelines ... #algorithm #rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
thiazidic, PPI, ACE ... constitutional symptoms • Treatment ... life-threatening • Treatment ... comparison #table #rheumatology ... #diagnosis #management
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Incidence: common in APL ... Triggers: ATRA treatment ... Renal Failure Treatment ... #management #hematology ... #oncology
Paraproteinemias

Entities That Can Feature A Monoclonal Protein/M Component:
• MM
• WM
• MGUS
• MGCS
• MGRS
• Splenic Marginal Zone
Evans • ITP • Cl-NH ... Pseudohyponatremia • ↓anion gap ... Paraproteinemias #Hematology ... #Differential #Diagnosis ... #Oncology
Hodgkin's Lymphoma Overview

Hodgkin's lymphoma (HL) is an uncommon hematological malignancy arising from mature B cells. It
accounts for 10% of all ... lymph node biopsy (diagnostic ... Hodgkin Lymphoma Treatment ... Hodgkins #lymphoma #diagnosis ... #oncology #management
Myelodysplastic Syndromes (MDS)

What?
Myelodysplastic syndromes are a group of disorders caused by blood cells that are poorly
factor (GCSF) treatments ... marrow studies Treatment ... Immunosuppressive treatment ... Myelodysplastic #Syndromes #diagnosis ... #hematology #oncology
Drug Induced Lupus (DIL)
 • Epidemiology: -10% of all lupus cases, drug-dependent, 4:1 to 1:1 F:M
Epidemiology: -10% of all ... thiazidic, PPI, ACE ... constitutional symptoms • Treatment ... DrugInduced #Lupus #DIL #rheumatology ... #diagnosis #treatment